203 related articles for article (PubMed ID: 37043210)
21. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
Mukhtar RA; Chau H; Woriax H; Piltin M; Ahrendt G; Tchou J; Yu H; Ding Q; Dugan CL; Sheade J; Crown A; Carr M; Wong J; Son J; Yang R; Chan T; Terando A; Alvarado M; Ewing C; Tonneson J; Tamirisa N; Gould R; Singh P; Godellas C; Larson K; Chiba A; Rao R; Sauder C; Postlewait L; Lee MC; Symmans WF; Esserman LJ; Boughey JC;
Ann Surg; 2023 Sep; 278(3):320-327. PubMed ID: 37325931
[TBL] [Abstract][Full Text] [Related]
22. Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM; Patel A; Catalfamo K; Attwood K; Khoury T; Yao S; Gandhi S
JAMA Netw Open; 2023 Nov; 6(11):e2344517. PubMed ID: 37991763
[TBL] [Abstract][Full Text] [Related]
23. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
[TBL] [Abstract][Full Text] [Related]
24. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
Yanez B; Gray RJ; Sparano JA; Carlos RC; Sadigh G; Garcia SF; Gareen IF; Whelan TJ; Sledge GW; Cella D; Wagner LI
JAMA Oncol; 2021 Jun; 7(8):1-7. PubMed ID: 34137783
[TBL] [Abstract][Full Text] [Related]
25. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
[No Abstract] [Full Text] [Related]
26. State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women.
Sung H; Wiese D; Jatoi I; Jemal A
JAMA Oncol; 2023 May; 9(5):700-704. PubMed ID: 36862439
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
28. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
29. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
30. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.
Zumsteg ZS; Morrow M; Arnold B; Zheng J; Zhang Z; Robson M; Traina T; McCormick B; Powell S; Ho AY
Ann Surg Oncol; 2013 Oct; 20(11):3469-76. PubMed ID: 23686101
[TBL] [Abstract][Full Text] [Related]
31. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
32. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer.
Cho B; Han Y; Lian M; Colditz GA; Weber JD; Ma C; Liu Y
JAMA Oncol; 2021 Jul; 7(7):1016-1023. PubMed ID: 33983438
[TBL] [Abstract][Full Text] [Related]
34. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
36. Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
Jwa E; Shin KH; Lim HW; Jung SY; Lee S; Kang HS; Lee E; Park YH
PLoS One; 2015; 10(12):e0145463. PubMed ID: 26691445
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
38. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
39. Racial and Ethnic Bias in Risk Prediction Models for Colorectal Cancer Recurrence When Race and Ethnicity Are Omitted as Predictors.
Khor S; Haupt EC; Hahn EE; Lyons LJL; Shankaran V; Bansal A
JAMA Netw Open; 2023 Jun; 6(6):e2318495. PubMed ID: 37318804
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
